Increased risk for the development of prostatic hyperplasia in older patients. Exclude carcinoma of prostate before starting therapy w/ testosterone prep. Regular exam of prostate is recommended in men. Periodically check Hb & hematocrit in patients on long-term androgen therapy to detect cases of polycythemia. Risk of bleeding in patients w/ acquired or inherited bleeding disorders. Concomitant use w/ coumarin derived oral anticoagulants. Patients w/ thrombophilia. Consider liver tumor in the differential diagnostic if severe upper abdominal complaints, liver enlargement or signs of intra-abdominal hemorrhage occur in men. Patients predisposed to edema eg, cases of severe cardiac, hepatic or renal insufficiency or ischemic heart disease; men w/ HTN. Discontinue treatment immediately in case of severe complications characterized by edema w/ or w/o CHF. Can cause accelerated growth, bone maturation & premature epiphyseal closure in childn. Appearance of common acne. Preexisting sleep apnea may be potentiated. May subject to abuse at higher doses & in combination w/ other anabolic androgenic steroids resulting to dependence & w/drawal symptoms upon significant dose reduction or abrupt discontinuation. Strictly must be injected IM & very slowly as pulmonary microembolism of oily soln occurs rarely & may lead to cough, dyspnoea, malaise, hyperhydrosis, chest pain, dizziness, paraesthesia, or syncope. Suspected anaphylactic reactions. May reversibly reduce spermatogenesis. Childn & adolescent <18 yr.
Sign Out
